Table 1.
Main characteristics and results of studies evaluating the MVD and survival
| First author | Year | Patients source | Study design | N | Blinded reading | Readers (n) | Mode of reading | Follow-up (years) | Anti-body | Cut-off | HR estimation | Survival analysis | Results |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Iakovlev [36] | 2012 | Canada | Retro. | 57 | Yes | ? | Automated | 3.25 | CD34 | Median | ND | DFS | Negative |
| Ren [35] | 2011 | China | Retro. | 128 | Yes | 2 | Optical | ? | CD34 | Median | HR | OS | Negative |
| Yao a [34] | 2007 | China | Retro. | 78 | ? | ? | Automated | ? | CD31 | Median | HR | OS | Negative |
| Yao b [34] | 2007 | China | Retro. | 78 | ? | ? | Automated | ? | CD34 | Median | HR | OS | Negative |
| Kawata [33] | 2004 | Japan | Retro. | 17 | ? | ? | Automated | 3.17 | FVIII | Median | RR | OS | Negative |
| Yagasaki [32] | 2003 | Japan | Retro. | 84 | ? | ? | Optical | 2.75 | CD105 | Median | HR | OS | Negative |
| Sabo [17] | 2001 | Israel | Retro. | 49 | ? | ? | Automated | ? | CD34 | > 10% | ND | OS | Negative |
| Song [31] | 2001 | Korea | Retro. | 50 | ? | 2 | Optical | 8 | CD31 | > 10 vessels | Surv. curves | OS | Positive |
| Yoshino [30] | 2000 | Japan | Retro. | 96 | Yes | 2 | Optical | > 5 | FVIII | Median | ND | OS | Positive |
| Nativ [20] | 1998 | Israel | Retro. | 36 | ? | ? | Optical | 8.1 | FVIII | Median | Events | OS | Positive |
| Yoshino [29] | 1998 | Japan | Retro. | 62 | ? | ? | Optical | ? | FVIII | Median | Events | OS | Positive |
| Gelb [28] | 1997 | USA | Retro. | 52 | ? | ? | Optical | 9.08 | FVIII | Median | ND | OS | Negative |
| Imazano [27] | 1997 | Japan | Retro. | 133 | ? | ? | ? | 3.33 | FVIII | ? | HR | OS | Negative |
| Delahunt [26] | 1997 | New Zealand | Retro. | 150 | ? | 3 | Optical | ? | FVIII | > 40 vessels/HPF | ND | OS | Negative |
| Yoshino [21] | 1995 | Japan | Retro. | 45 | Yes | ? | Optical | 2.17 | FVIII | Median | Events | OS, DFS (ND) | Positive |
MVD, micro vessel density; Retro, retrospective study; HPF, high power field; HR, hazard ratio; ND, no data; OS, overall survival; DFS, disease-free survival; Positive MVD, being significantly unfavorable prognostic factor for overall survival; Negative MVD, being significantly favorable or no significant prognostic factor for overall survival.